InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2025-10-07 | Xu Jiandong | Chief Financial Officer | Purchase | 1,000 | $1.33 | $1K | 265.5K | View ↗ | |
| 2025-09-22 | Xu Jiandong | Chief Financial Officer | Purchase | 1,000 | $1.16 | $1K | 16.7K | View ↗ | |
| 2025-09-11 | Xu Jiandong | Chief Financial Officer | Purchase | 100 | $1.04 | $104.00 | 264.6K | View ↗ |
| Metric | FY2025 | FY2024 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Research and development (including $10,125,000 for the year ended December 31, 2025 and $2,801,435 for the six months ended December 31, 2024, from a related party) | $10.2M+258.5% | $2.9M | — | — | — |
| General and administrative | $2.8M+79.4% | $1.6M-51.0% | $3.2M+382.7% | $663K | — |
| Total operating expenses | $13.1M+195.1% | $4.4M-39.4% | $7.3M-34.2% | $11.1M | — |
| Loss from Operations | -$13.1M-195.1% | -$4.4M+39.4% | -$7.3M+34.2% | -$11.1M-608.1% | -$1.6M |
| Loss before income taxes | -$13.1M-195.1% | -$4.4M+39.4% | -$7.3M+34.2% | -$11.1M-1114.1% | -$915K |
| Income tax provision | -$838-1230.2% | -$63 | — | — | — |
| Net loss | -$13.1M-195.1% | -$4.4M+39.5% | -$7.3M+34.2% | -$11.1M | — |
| Net loss applicable to common stock per share, basic (in Dollars per share) | -$0.35-191.7% | -$0.12+55.6% | -$0.27+99.3% | -$36.35 | — |
| Net loss applicable to common stock per share, diluted (in Dollars per share) | -$0.35-191.7% | -$0.12 | — | — | — |
| Weighted average common stock outstanding, basic (in Shares) | $36.8M+0.8% | $36.5M+34.7% | $27.1M+8764.8% | $306K | — |
| Weighted average common stock outstanding, diluted (in Shares) | $36.8M+0.8% | $36.5M | — | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T
ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®